Physician
Samaritan Hospital of Troy, New York
Samaritan Hospital of Troy, New York was paid $132.15M by Medicaid between Jan 2018 and Dec 2024, across 542 billing codes. Its largest line is G9005, Coordinated care fee, risk adjusted maintenance — 33% of everything it billed.
33Billing provider infoSAMARITAN HOSPITAL OF TROY, NEW YORK
TROY, NY 12180
TROY, NY 12180
33aNPI1043267727assigned 05/28/2006
33bProvider typeRadiation Oncology Physician
28Total paid$132.15M
24GClaims2,081,354
24DCodes billed542
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Radiation Oncology Physician providers in New York
Rank by total paid#1 of 80
Median peer was paid$12K
This provider vs. median10,755×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,647 | $51K | |
| 2019 | 121,275 | $8.69M | |
| 2020 | 338,092 | $19.83M | |
| 2021 | 371,388 | $23.36M | |
| 2022 | 418,287 | $26.20M | |
| 2023 | 473,255 | $30.42M | |
| 2024incomplete | 355,410 | $23.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G9005 | Coordinated care fee, risk adjusted maintenance | 33% | 131,014 | 131,014 | $43.35M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.0% | 52,531 | 48,786 | $6.63M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.8% | 40,245 | 37,866 | $5.02M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.4% | 58,838 | 52,017 | $4.54M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.0% | 46,888 | 39,615 | $3.95M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.4% | 41,365 | 38,206 | $3.15M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.4% | 15,159 | 12,828 | $3.14M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.4% | 26,081 | 24,648 | $3.14M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 22,795 | 21,763 | $2.88M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 10,818 | 10,595 | $2.65M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.9% | 9,786 | 4,000 | $2.57M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.8% | 44,015 | 14,290 | $2.44M |
530 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 8,918 | $2.25M |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.5% | 5,971 | $1.97M |
| 90834 | Psychotherapy session, about 45 minutes | 1.4% | 20,314 | $1.81M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 3,070 | $1.69M |
| H2019 | Therapeutic behavioral services, billed per 15 minutes | 1.2% | 2,979 | $1.60M |
| 80053 | Comprehensive metabolic panel | 1.2% | 79,646 | $1.57M |
| 93975 | 1.2% | 5,270 | $1.53M | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 18,368 | $1.27M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 8,797 | $1.10M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,656 | $1.09M |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,677 | $1.08M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 14,320 | $1.07M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,118 | $950K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,589 | $866K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 25,625 | $753K |
| 36415 | Collection of venous blood by venipuncture | <1% | 133,842 | $736K |
| 11045 | <1% | 987 | $727K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 8,540 | $627K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 15,301 | $618K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 14,572 | $594K |
| 12001 | <1% | 1,475 | $579K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,740 | $577K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 872 | $566K |
| J2323 | Injection, natalizumab, 1 mg | <1% | 107 | $546K |
| 76770 | <1% | 1,744 | $527K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15,499 | $485K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 10,120 | $484K |
| H2018 | Psychosocial rehabilitation services, per diem | <1% | 1,240 | $472K |
| G0378 | Hospital observation service, per hour | <1% | 4,717 | $458K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,261 | $456K |
| 93970 | <1% | 1,121 | $451K | |
| Q3014 | Telehealth originating site facility fee | <1% | 14,462 | $438K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 875 | $379K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 1,318 | $355K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,926 | $354K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,863 | $351K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 3,763 | $350K |
| 97161 | <1% | 4,075 | $339K | |
| 12011 | <1% | 840 | $328K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,829 | $325K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 9,652 | $324K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 15,502 | $311K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 17,872 | $310K |
| 76801 | <1% | 3,268 | $309K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 3,996 | $305K |
| 70496 | <1% | 1,180 | $300K | |
| 10060 | <1% | 1,070 | $300K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 3,816 | $291K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 3,272 | $282K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 5,497 | $275K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,648 | $273K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 3,388 | $268K |
| 76830 | Ultrasound, transvaginal | <1% | 5,732 | $250K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,930 | $223K |
| 29125 | <1% | 1,159 | $223K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 2,335 | $219K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 2,601 | $217K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,204 | $215K |
| 97162 | <1% | 2,076 | $204K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,544 | $199K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 25,020 | $198K |
| 64400 | <1% | 502 | $197K | |
| 0223U | <1% | 843 | $191K | |
| 70491 | <1% | 704 | $187K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,753 | $184K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 260 | $183K |
| 76641 | <1% | 3,757 | $182K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 415 | $181K |
| 86900 | <1% | 5,859 | $180K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,714 | $178K |
| 71250 | <1% | 1,488 | $161K | |
| 93971 | <1% | 2,798 | $159K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,627 | $158K |
| 88342 | <1% | 3,266 | $158K | |
| 80061 | Lipid panel | <1% | 15,193 | $157K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,878 | $157K |
| 29515 | <1% | 824 | $155K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,573 | $152K |
| 86850 | <1% | 5,367 | $146K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,810 | $143K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 18,554 | $136K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,047 | $132K |
| 12002 | <1% | 326 | $131K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,578 | $131K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 403 | $130K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 16,994 | $129K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 22,007 | $127K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 8,784 | $127K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,453 | $122K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 6,723 | $122K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 28,623 | $121K |
| 83880 | <1% | 4,288 | $115K | |
| 90715 | <1% | 4,541 | $113K | |
| 87634 | <1% | 2,432 | $112K | |
| G9001 | Coordinated care fee, initial rate | <1% | 1,489 | $112K |
| 99385 | <1% | 1,113 | $109K | |
| 86901 | <1% | 5,868 | $106K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 572 | $102K |
| 70498 | <1% | 1,170 | $102K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,757 | $100K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,132 | $100K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,009 | $99K |
| 97035 | <1% | 5,572 | $97K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,088 | $96K |
| 90837 | Psychotherapy session, about an hour | <1% | 1,118 | $94K |
| 70486 | <1% | 1,437 | $93K | |
| 97165 | <1% | 1,223 | $90K | |
| 77066 | Tomosynthesis, mammo | <1% | 956 | $89K |
| 59025 | Fetal non-stress test | <1% | 563 | $89K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,468 | $83K |
| 76536 | <1% | 1,755 | $78K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 71,878 | $78K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,746 | $78K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,360 | $75K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13,073 | $73K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 239 | $73K |
| 90686 | <1% | 4,057 | $71K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 10,992 | $70K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,441 | $70K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 223 | $70K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 845 | $69K |
| 76775 | <1% | 1,199 | $64K | |
| 77080 | <1% | 856 | $63K | |
| 88142 | <1% | 2,648 | $63K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 767 | $63K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 164 | $62K |
| 85610 | <1% | 13,543 | $61K | |
| 71271 | <1% | 1,053 | $60K | |
| 36416 | <1% | 4,406 | $56K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 482 | $54K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 654 | $47K |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 824 | $46K |
| 99223 | Prolong inpt eval add15 m | <1% | 487 | $45K |
| 87428 | <1% | 1,285 | $42K | |
| 84439 | <1% | 7,504 | $41K | |
| 96367 | <1% | 814 | $41K | |
| 82607 | <1% | 4,435 | $39K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 20,554 | $39K |
| 90461 | <1% | 2,745 | $39K | |
| 29505 | <1% | 202 | $39K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 955 | $38K |
| 74183 | <1% | 96 | $37K | |
| 77062 | <1% | 358 | $35K | |
| 90651 | <1% | 1,190 | $34K | |
| 99406 | <1% | 1,930 | $34K | |
| 86780 | <1% | 4,379 | $34K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,840 | $33K |
| 93976 | <1% | 84 | $32K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 170 | $32K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 106 | $32K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 748 | $31K |
| 72131 | <1% | 314 | $31K | |
| 99386 | <1% | 318 | $30K | |
| 97116 | <1% | 1,004 | $30K | |
| 47562 | <1% | 12 | $30K | |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 44 | $29K |
| 82805 | <1% | 2,713 | $29K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 33,790 | $28K |
| 95806 | <1% | 468 | $27K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 53 | $25K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 598 | $24K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 15 | $24K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 334 | $24K |
| 86703 | <1% | 1,634 | $24K | |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 223 | $23K |
| 90670 | <1% | 1,432 | $23K | |
| 87660 | <1% | 6,665 | $23K | |
| 82728 | <1% | 3,820 | $22K | |
| 72100 | <1% | 1,605 | $22K | |
| 90677 | <1% | 773 | $22K | |
| 76870 | <1% | 873 | $22K | |
| 90633 | <1% | 1,181 | $21K | |
| 87480 | <1% | 6,509 | $20K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,527 | $20K |
| 80047 | <1% | 929 | $20K | |
| 85027 | <1% | 10,234 | $19K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 357 | $19K |
| 83655 | <1% | 1,616 | $19K | |
| 90648 | <1% | 1,193 | $19K | |
| 0352U | <1% | 994 | $19K | |
| 88304 | <1% | 572 | $19K | |
| 87510 | <1% | 6,474 | $19K | |
| 81025 | <1% | 6,311 | $18K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 1,020 | $17K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 167 | $17K |
| 90734 | <1% | 881 | $16K | |
| 86803 | <1% | 2,372 | $16K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 801 | $16K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 896 | $16K |
| 82746 | <1% | 1,822 | $16K | |
| 77061 | <1% | 194 | $15K | |
| 73630 | <1% | 3,054 | $15K | |
| 87653 | <1% | 609 | $15K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 592 | $15K |
| 74018 | <1% | 1,387 | $15K | |
| 82043 | <1% | 3,651 | $14K | |
| 90723 | <1% | 770 | $14K | |
| 83970 | <1% | 514 | $14K | |
| 73564 | <1% | 1,973 | $14K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 2,058 | $14K |
| 81001 | <1% | 26,632 | $13K | |
| 87563 | <1% | 683 | $13K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 210 | $13K |
| 84153 | <1% | 870 | $13K | |
| 99460 | <1% | 283 | $13K | |
| 86480 | <1% | 313 | $13K | |
| 90698 | <1% | 763 | $12K | |
| 84702 | <1% | 6,228 | $12K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 40 | $12K |
| 74178 | <1% | 64 | $11K | |
| T1017 | Case management, billed per 15 minutes | <1% | 68 | $11K |
| 36430 | <1% | 43 | $11K | |
| H0031 | Mental health assessment, by non-physician | <1% | 60 | $11K |
| 90674 | <1% | 410 | $11K | |
| 73030 | <1% | 2,371 | $11K | |
| 83735 | <1% | 13,095 | $11K | |
| 97014 | <1% | 594 | $11K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 630 | $10K |
| 83540 | <1% | 3,119 | $10K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 436 | $10K |
| 29130 | <1% | 53 | $10K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 28 | $10K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 510 | $10K |
| 87340 | <1% | 1,999 | $10K | |
| 96415 | <1% | 146 | $9K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 238 | $9K |
| 86618 | <1% | 1,516 | $9K | |
| 82570 | <1% | 2,862 | $9K | |
| 90681 | <1% | 388 | $9K | |
| 84481 | <1% | 974 | $8K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 97 | $8K |
| 90680 | <1% | 479 | $8K | |
| 87150 | <1% | 264 | $8K | |
| 99205 | Prolong outpt/office vis | <1% | 78 | $8K |
| 83550 | <1% | 2,096 | $8K | |
| 86580 | <1% | 598 | $8K | |
| 73502 | <1% | 1,039 | $7K | |
| 81003 | <1% | 14,071 | $7K | |
| 90682 | <1% | 302 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,554 | $7K |
| 86762 | <1% | 1,217 | $7K | |
| 73610 | <1% | 2,716 | $7K | |
| 54150 | <1% | 101 | $7K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 16 | $7K |
| 80074 | <1% | 366 | $7K | |
| 88307 | <1% | 103 | $7K | |
| 80076 | <1% | 839 | $7K | |
| 90656 | <1% | 518 | $7K | |
| 73130 | <1% | 2,558 | $7K | |
| 94060 | <1% | 77 | $6K | |
| 86038 | <1% | 874 | $6K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,144 | $6K |
| 90744 | <1% | 369 | $6K | |
| 74174 | <1% | 53 | $6K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 47 | $6K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 966 | $6K |
| 73562 | <1% | 877 | $5K | |
| 84403 | <1% | 236 | $5K | |
| 90707 | <1% | 277 | $5K | |
| 90710 | <1% | 260 | $5K | |
| 86140 | <1% | 2,568 | $5K | |
| 0002A | <1% | 136 | $5K | |
| 86765 | <1% | 892 | $5K | |
| 99442 | <1% | 89 | $4K | |
| 87186 | <1% | 3,432 | $4K | |
| 94760 | <1% | 37,185 | $4K | |
| 90620 | <1% | 205 | $4K | |
| J3490 | Unclassified drugs | <1% | 279 | $4K |
| 72141 | <1% | 12 | $4K | |
| 97166 | <1% | 54 | $4K | |
| 86769 | <1% | 119 | $4K | |
| 86696 | <1% | 455 | $4K | |
| 86235 | <1% | 88 | $4K | |
| 90716 | <1% | 195 | $4K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 223 | $4K |
| 87077 | <1% | 3,808 | $4K | |
| 99404 | <1% | 43 | $4K | |
| 86617 | <1% | 405 | $4K | |
| 73110 | <1% | 1,581 | $4K | |
| 83690 | <1% | 19,012 | $4K | |
| 99401 | <1% | 81 | $4K | |
| 86787 | <1% | 848 | $4K | |
| 87507 | <1% | 27 | $3K | |
| 92551 | <1% | 52 | $3K | |
| 0011A | <1% | 142 | $3K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 128 | $3K |
| 82550 | <1% | 1,962 | $3K | |
| 96127 | <1% | 1,773 | $3K | |
| 84550 | <1% | 1,175 | $3K | |
| 90661 | <1% | 117 | $3K | |
| 90696 | <1% | 157 | $3K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 53 | $3K |
| 87468 | <1% | 88 | $3K | |
| 82784 | <1% | 367 | $3K | |
| 86701 | <1% | 317 | $3K | |
| 90700 | <1% | 118 | $3K | |
| 84484 | <1% | 21,611 | $3K | |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 477 | $3K |
| 84703 | <1% | 22,404 | $3K | |
| 0001A | <1% | 157 | $3K | |
| 0012A | <1% | 97 | $3K | |
| 73140 | <1% | 1,202 | $3K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 211 | $3K |
| 93000 | <1% | 732 | $3K | |
| 86431 | <1% | 570 | $3K | |
| 97760 | <1% | 172 | $3K | |
| 85018 | <1% | 1,500 | $3K | |
| 84100 | <1% | 2,266 | $3K | |
| 86706 | <1% | 435 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,325 | $2K |
| 97010 | <1% | 199 | $2K | |
| 0071A | <1% | 80 | $2K | |
| 83520 | <1% | 181 | $2K | |
| 93798 | <1% | 81 | $2K | |
| 85651 | <1% | 1,004 | $2K | |
| 97163 | <1% | 16 | $2K | |
| 74019 | <1% | 143 | $2K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 44 | $2K |
| 84146 | <1% | 148 | $2K | |
| 72040 | <1% | 106 | $2K | |
| 87088 | <1% | 927 | $2K | |
| 85652 | <1% | 2,424 | $2K | |
| 85379 | <1% | 3,850 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 51 | $2K |
| 82947 | <1% | 1,849 | $2K | |
| 87070 | <1% | 1,713 | $2K | |
| 83001 | <1% | 115 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,589 | $2K |
| 0124A | <1% | 116 | $2K | |
| 86695 | <1% | 261 | $2K | |
| 73560 | <1% | 173 | $2K | |
| 83002 | <1% | 98 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,783 | $2K |
| 99221 | <1% | 27 | $1K | |
| 81329 | <1% | 13 | $1K | |
| 86200 | <1% | 142 | $1K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 12 | $1K |
| H0014 | Alcohol and/or drug services; ambulatory detoxification | <1% | 12 | $1K |
| 84425 | <1% | 78 | $1K | |
| 99381 | <1% | 12 | $1K | |
| 99001 | <1% | 195 | $1K | |
| 85730 | <1% | 3,273 | $1K | |
| 73590 | <1% | 639 | $1K | |
| 81002 | <1% | 3,188 | $1K | |
| 99383 | <1% | 12 | $1K | |
| 86141 | <1% | 199 | $1K | |
| 90480 | <1% | 133 | $1K | |
| J2680 | Injection, fluphenazine decanoate, up to 25 mg | <1% | 91 | $1K |
| 82950 | <1% | 289 | $1K | |
| 84402 | <1% | 44 | $1K | |
| 90673 | <1% | 40 | $1K | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 57 | $1K |
| 0072A | <1% | 41 | $1K | |
| 96368 | <1% | 35 | $1K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,708 | $1K |
| 82248 | <1% | 355 | $1K | |
| 83615 | <1% | 980 | $1K | |
| 76642 | <1% | 26 | $1K | |
| 96376 | <1% | 4,975 | $981.71 | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 61 | $975.96 |
| 73080 | <1% | 728 | $953.80 | |
| 0064A | <1% | 47 | $934.13 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 15,697 | $926.55 |
| 82150 | <1% | 388 | $897.82 | |
| 97032 | <1% | 51 | $884.37 | |
| 94729 | <1% | 78 | $858.80 | |
| 83525 | <1% | 85 | $837.16 | |
| 94726 | <1% | 52 | $835.39 | |
| 83516 | <1% | 76 | $823.29 | |
| 91320 | <1% | 69 | $769.65 | |
| 0004A | <1% | 52 | $752.35 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,091 | $726.26 |
| 86920 | <1% | 31 | $717.08 | |
| 90662 | <1% | 76 | $699.05 | |
| 90685 | <1% | 39 | $678.30 | |
| 82105 | <1% | 88 | $625.35 | |
| 71101 | <1% | 144 | $612.80 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,063 | $595.54 |
| 83605 | <1% | 6,496 | $592.31 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 13 | $592.13 |
| 87040 | <1% | 3,884 | $577.48 | |
| 92250 | <1% | 14 | $576.30 | |
| 87147 | <1% | 301 | $558.06 | |
| 0054A | <1% | 30 | $554.95 | |
| 94010 | <1% | 14 | $540.76 | |
| G0008 | Administration of influenza virus vaccine | <1% | 126 | $539.78 |
| 87205 | <1% | 778 | $502.99 | |
| 94664 | <1% | 856 | $473.87 | |
| 86225 | <1% | 73 | $464.33 | |
| 90619 | <1% | 28 | $453.34 | |
| 84156 | <1% | 243 | $445.63 | |
| 87210 | <1% | 393 | $420.60 | |
| 72070 | <1% | 24 | $420.03 | |
| 70360 | <1% | 25 | $416.21 | |
| 73090 | <1% | 342 | $400.42 | |
| 85014 | <1% | 1,228 | $390.02 | |
| 36591 | <1% | 103 | $389.58 | |
| 88341 | <1% | 25 | $365.05 | |
| 85007 | <1% | 1,718 | $357.32 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 41 | $343.47 |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 160 | $313.12 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 132 | $294.79 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 266 | $293.25 |
| 86665 | <1% | 13 | $290.24 | |
| 99441 | <1% | 14 | $279.22 | |
| 90621 | <1% | 12 | $263.59 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 792 | $263.24 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,939 | $251.31 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 68 | $237.12 |
| 87581 | <1% | 13 | $236.52 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,016 | $230.05 |
| 71100 | <1% | 26 | $219.23 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 548 | $218.72 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,645 | $214.23 |
| C1769 | Guide wire | <1% | 387 | $205.04 |
| 86376 | <1% | 13 | $198.82 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 933 | $193.28 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 626 | $186.78 |
| 86308 | <1% | 717 | $184.55 | |
| 86800 | <1% | 12 | $182.28 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,252 | $177.32 |
| 73660 | <1% | 50 | $166.44 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 478 | $160.90 |
| 80348 | <1% | 196 | $160.50 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,462 | $145.31 |
| 82247 | <1% | 266 | $139.23 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 277 | $138.54 |
| 86300 | <1% | 14 | $126.21 | |
| 80362 | <1% | 488 | $124.45 | |
| 82270 | <1% | 139 | $124.07 | |
| 84436 | <1% | 108 | $122.82 | |
| 86664 | <1% | 12 | $122.32 | |
| 99358 | Prolong nursin fac eval 15m | <1% | 546 | $112.58 |
| 84480 | <1% | 14 | $111.28 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 15 | $106.10 |
| J2704 | Injection, propofol, 10 mg | <1% | 5,044 | $101.94 |
| 87641 | <1% | 12 | $98.59 | |
| 82040 | <1% | 273 | $96.45 | |
| 72170 | <1% | 92 | $95.08 | |
| 86364 | <1% | 16 | $94.55 | |
| 86334 | <1% | 21 | $90.70 | |
| 87185 | <1% | 36 | $88.99 | |
| 80164 | <1% | 24 | $85.23 | |
| 84132 | <1% | 767 | $82.81 | |
| 80354 | <1% | 410 | $79.74 | |
| 80177 | <1% | 37 | $79.72 | |
| 87207 | <1% | 465 | $78.43 | |
| 84460 | <1% | 81 | $77.34 | |
| 86735 | <1% | 12 | $77.25 | |
| 86666 | <1% | 33 | $66.16 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,265 | $60.11 |
| 84450 | <1% | 43 | $55.48 | |
| 86704 | <1% | 13 | $54.09 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,730 | $52.09 |
| 84165 | <1% | 24 | $48.70 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,122 | $46.00 |
| 82140 | <1% | 13 | $43.71 | |
| 87075 | <1% | 55 | $42.23 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,515 | $40.77 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 195 | $34.32 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,850 | $31.87 |
| 82565 | <1% | 26 | $31.86 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 56 | $30.47 |
| 73620 | <1% | 14 | $30.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 226 | $29.69 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,014 | $29.20 |
| 80320 | <1% | 988 | $28.75 | |
| 82803 | <1% | 332 | $28.35 | |
| 84155 | <1% | 185 | $26.76 | |
| 87073 | <1% | 97 | $26.08 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,878 | $25.71 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 416 | $24.31 |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | <1% | 14 | $23.03 |
| 82272 | <1% | 26 | $15.69 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 535 | $15.50 |
| 84075 | <1% | 90 | $14.59 | |
| 81015 | <1% | 829 | $13.04 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 387 | $12.91 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 543 | $12.48 |
| 82310 | <1% | 80 | $11.42 | |
| 83721 | <1% | 42 | $10.50 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 833 | $8.97 |
| 81000 | <1% | 81 | $8.14 | |
| 80329 | <1% | 205 | $8.02 | |
| 82962 | <1% | 274 | $7.47 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,015 | $6.72 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,733 | $6.54 |
| A9270 | Non-covered item or service | <1% | 192 | $6.36 |
| J1815 | Injection, insulin, per 5 units | <1% | 633 | $5.21 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 831 | $4.83 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 469 | $2.30 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,817 | $2.19 |
| 73060 | <1% | 42 | $0.14 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 13 | $0.13 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 268 | $0.09 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 140 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 126 | $0.00 |
| G9920 | Screening performed and negative | 0% | 431 | $0.00 |
| 3078F | 0% | 6,234 | $0.00 | |
| 99354 | 0% | 12 | $0.00 | |
| 99359 | Prolong nursin fac eval 15m | 0% | 206 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 70 | $0.00 |
| 87400 | 0% | 32 | $0.00 | |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | 0% | 58 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 75 | $0.00 |
| 97012 | 0% | 28 | $0.00 | |
| 91300 | 0% | 90 | $0.00 | |
| S9401 | Anticoagulation clinic, inclusive of all services except laboratory tests, per session | 0% | 241 | $0.00 |
| 3077F | 0% | 27 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 26 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 12 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 16 | $0.00 |
| A4312 | Insertion tray without drainage bag with indwelling catheter, foley type, two-way, all silicone | 0% | 12 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 21 | $0.00 |
| 3074F | 0% | 8,287 | $0.00 | |
| 3008F | 0% | 3,923 | $0.00 | |
| 3079F | 0% | 1,434 | $0.00 | |
| 3075F | 0% | 145 | $0.00 | |
| 90474 | 0% | 43 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 160 | $0.00 |
| 3044F | 0% | 698 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 181 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 14 | $0.00 |
| 3080F | 0% | 14 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 14 | $0.00 |
| 1220F | 0% | 56 | $0.00 | |
| 91301 | 0% | 87 | $0.00 | |
| A4344 | Indwelling catheter, foley type, two-way, all silicone or polyurethane, each | 0% | 12 | $0.00 |
| 87807 | 0% | 19 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTERK, GARY (CREDENTIALING MANAGER)
Parent organizationSAMARITAN HOSPITAL OF TROY, NEW YORK
| Provider | Location | Paid |
|---|---|---|
| ST. Peter's Hospital of the City of Albany | Albany, NY | $35.39M |
| ST. Peter's Health Partners Medical Associates, P.C. | Albany, NY | $6.57M |
| Sunnyview Hospital and Rehabilitation Center | Schenectady, NY | $3.89M |
| ST. Peter's Health Partners Medical Associates, P.C. | Troy, NY | $70K |
| ST. Peter's Health Partners Medical Associates, P.C. | Saratoga Springs, NY | $46K |
| ST. Peter's Health Partners Medical Associates, P.C. | Albany, NY | $6K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.